Thoughts and resources about health, drugs and prescriptions, and how they are affected by GMPs (FDA Good Manufacturing Practices) and other regulations.
Executive Summary Priority 1. Fully Implement a Total Product Life Cycle Approach
Strategy 1.1. Enhance and Integrate Premarket, Postmarket, and Compliance Information and Functions
Strategy 1.2. Improve Guidance and Regulation Development
Strategy 1.3. Develop a Cross-Center Compliance Strategy Priority 2. Enhance Communication and Transparency
Strategy 2.1. Develop a Strategic Approach to Public Communication
Strategy 2.2. Improve Internal Communications
Strategy 2.3. Increase Transparency in Decision Making Priority 3. Strengthen Our Workforce and Workplace
Strategy 3.1. Recruit, Develop, and Retain High-Quality Employees
Strategy 3.2. Leverage External Expertise
Strategy 3.3. Establish Pathways for Resolving Differences of Opinion
Strategy 3.4. Improve Internal Administrative Processes
Strategy 3.5. Make CDRH's White Oak Facilities More Workplace-Friendly Priority 4. Proactively Facilitate Innovation and Address Unmet Public Health Needs
Strategy 4.1. Foster Development of Medical Devices to Respond to Unmet Public Health Needs
Strategy 4.2. Develop a Personalized Medicine Program
The U.S. Food and Drug Administration (FDA) is warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit). The counterfeit Alli product looks similar to the authentic product, with a few notable differences. The counterfeit Alli has:
Outer cardboard packaging missing a “Lot” code;
Expiration date that includes the month, day, and year (e.g., 06162010); authentic Alli expiration date includes only the month and year (e.g.,: 05/12);
Packaging in a plastic bottle that has a slightly taller and wider cap with coarser ribbing than the genuine product;
Plain foil inner safety seal under the plastic cap without any printed words; the authentic product seal is printed with “SEALED for YOUR PROTECTION”;
Contains larger capsules with a white powder, instead of small white pellets.
Consumers who believe they have received counterfeit Alli are asked to contact the FDA's Office of Criminal Investigations (OCI) by calling 800-551-3989 or by visiting the OCI Web site (http://www.fda.gov/OCI).
"The best “guesstimate” is that 1% of drugs in the developed world are counterfeit. In developing nations, between 10 and 50% of drugs are thought to be fake."
"Is it possible to stop medicines counterfeiting altogether? I doubt very much whether it is. All we can do is to try our best to secure the supply chain."
Devicemakers and importers can expect delays for inspections and screenings because the FDA is putting their trainees at US borders, reports FDAnews Device Daily Bulletin, Devicemakers May Face More Inspections, Delays in 2010:
"New employees probably will be trained at the borders because that’s where the highest volume of regulated commodities can be found"
A federal judge says the FDA (Food and Drug Administration) overstepped its authority in efforts to regulate electronic cigarettes, reports this Washington Post article, FDA can't block importing of 'electronic cigarettes'.
The FDA's position:
FDA says they've found cancer-causing ingredients in the products, despite manufacturers’ claims that they are safer than tobacco cigarettes.
The judge's position:
Electronic cigarettes are “the functional equivalent of traditional cigarettes."
Bottomline:
U.S. District Judge Richard J. Leon determined that electronic cigarettes are tobacco products and are not subject to restrictions.
I never heard about the FCPA (Foreign Corrupt Practices Act) until reading about it today. Wikipedia says FCPA addresses accounting transparency requirements under the Securities Exchange Act of 1934 and another concerning bribery of foreign officials.
Anyways, FDANews reports that the Department of Justice’s (DOJ) FCPA and healthcare fraud units are beginning to work together to investigate FCPA violations in the device and pharmaceutical industries. The DOJ has more information about FCPA on their website.
Here's why you need to care. The DOJ wants to aggressively enforce and investigate violations of the FCPA, targeting pharmaceutical and medical device companies as well as their individual executives and board members; this leaves them open to potentially massive legal and financial liabilities.
The FDA is warning the public about criminals posing as FDA special agents and other law enforcement personnel as part of an international extortion scam.
It goes something like this. The criminals call the victims (who in most cases previously purchased drugs over the Internet or via "telepharmacies") and identify themselves as FDA special agents or other law enforcement officials. The criminals inform the victims that purchasing drugs over the Internet or the telephone is illegal, and that law enforcement action will be pursued unless a fine or fee ranging from $100 to $250,000 is paid. Victims often also have fraudulent transactions placed against their credit cards. The criminals always request the money be sent by wire transfer to a designated location, usually a foreign county. If victims refuse to send money, they are often threatened with a search of their property, arrest, deportation, physical harm, and or incarceration.
Anyone receiving a telephone call from a person purporting to be an FDA or other law enforcement official who is seeking money to settle a law enforcement action for the illegal purchase of drugs over the Internet should refuse the demand and call the FDA’s Office of Criminal Investigations Metro Washington Field Office at (800) 521-5783 to report the crime.
So checkout this MSN Video, Holiday Hangover Cures, it walks through how to prevent a hangover, what to do while you're drinking, and last but not least, what to do if you get a hangover.
All data and information provided on this site is for informational purposes only. Drughealth.blogspot.com makes no representations as to accuracy, completeness, currentness, suitability, or validity of any information on this site and will not be liable for any errors, omissions, or delays in this information or any losses, injuries, or damages arising from its display or use. All information is provided on an as-is basis. We use third-party advertising companies to serve ads when you visit our website. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and to know your choices about not having this information used by these companies, click here.